FDA approves freeze-dried blood plasma for troops in combat

FDA approves freeze-dried blood plasma for troops in combat
© Getty Images

The Food and Drug Administration (FDA) on Tuesday approved freeze-dried blood plasma for use to treat combat injuries from U.S. troops, after a dispute over whether access would be allowed.

House Armed Services Committee Chairman Mac ThornberryWilliam (Mac) McClellan ThornberryOvernight Defense: Trump roils NATO on summit's first day | Trump, Merkel relationship sinks lower | House, Senate kick off defense bill talks | Senators symbolically rebuke Trump on national security tariffs Overnight Health Care: Pfizer delaying price hikes after Trump criticism | Dems focus on health care in Supreme Court fight | Feds won’t reunite all 102 detained children by deadline | VA nominee headed to Senate floor vote FDA approves freeze-dried blood plasma for troops in combat MORE (R-Texas) last year tried to go around the FDA by granting the Department of Defense the ability to allow the freeze-dried plasma use.

ADVERTISEMENT
Eventually, an agreement was reached to prevent that more drastic measure, and the FDA is now approving the use of the freeze-dried plasma from a French company, even though it is not approved for wider use in the United States.

“Through our collaborative program with the [Department of Defense], they’ve made clear the importance of access to freeze-dried plasma in initial efforts to control hemorrhage from battlefield trauma,” FDA Commissioner Scott Gottlieb said in a statement. “Granting this authorization will support access to this important product in the event it’s needed. The FDA remains deeply committed to implementing an enduring pathway to ensure that these potentially life-saving medical products are made available in the most expeditious, safe and effective manner possible.”

Plasma is used to help clot blood and stop bleeding, but it generally needs to be refrigerated. The freeze-dried plasma does not need to be refrigerated or go through a long thawing process the way normal frozen plasma, the FDA said, “thus enabling the rapid availability of plasma for use at the point of injury.”